RxDoctor Payments Data

Mark Koenig, MD

Interventional Cardiology · Nashville, TNNPI 1770521502

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,697 of the $10,793 with a category attached, or 71.3%. It is spread thinly across 36 manufacturers, the largest accounting for just 20.1%.

$10,793in general payments, 2019–2025

Across 153 payments — averaging $70.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Abbott$1K
  • Penumbra, Inc.$603
  • Recor Medical Inc$511
  • Shockwave Medical, Inc$358
  • plus $4K from 30 others
$103,476in research payments, 2019–2025

Across 44 payments — averaging $2351.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$98K
  • Recor Medical Inc$6K

What the payments were for

  • Travel & lodging$3,03528%
  • Food & beverage$7,69771%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,793 in reported general payments places this provider in the 60th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$243,951
Medicare patients
854
Services billed
2,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$150,234
EntrestoSacubitril/Valsartan166$143,350
Repatha SureclickEvolocumab154$137,336
FarxigaDapagliflozin Propanediol115$74,447
XareltoRivaroxaban72$70,843
JardianceEmpagliflozin52$46,006
BrilintaTicagrelor51$34,960
Praluent PenAlirocumab42$21,630
MultaqDronedarone Hcl20$19,791
NexlizetBempedoic Acid/Ezetimibe19$17,031
NexletolBempedoic Acid14$8,734
Ezetimibe306$8,284
Atorvastatin Calcium477$5,921
Prasugrel Hcl52$5,744
Ranolazine ErRanolazine74$5,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$150,234162 claims
NovartisEntresto$330$143,350166 claims
AstraZenecaFarxiga, Brilinta$83$109,407166 claims
Johnson & JohnsonXarelto$294$70,84372 claims
Boehringer IngelheimJardiance$15$46,00652 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$132$25,76533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →